Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18513750 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL15304150 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL13906437 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL16804783 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL13602972 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL19185841 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL16804784 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL14015255 | 1.00 | — | — | |
| SCHEMBL16274551 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 | |
| SCHEMBL15131931 | 1.00 | EPHX1 (0.39) | EPHX1HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | EPHX1 848/4885HIF1A 2913/4885ALDH1A1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.